Evidence map›Paper›PMID 26439959›Full record

ArticleJournal of neuroimmunology2015

Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis.

Adeline S L Ng, Joel Kramer, Alejandro Centurion, Josep Dalmau, Eric Huang, Jennifer A Cotter, Michael D Geschwind

Abstract readCase Reports
In one paragraph

Article in Journal of neuroimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. The role of the adenylate kinase 5 gene in various diseases and cancer.Journal of clinical and translational science · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Anti-Adenylate Kinase 5 Encephalitis With Histologic Evidence of CNS Vasculitis.Neurology(R) neuroimmunology & neuroinflammation · 2021
    Article
  9. Review
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Rapidly Progressive Dementia.Continuum (Minneapolis, Minn.) · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Adeline S L NgMemory and Aging Center, University of California, San Francisco, Sandler Neurosciences Centre, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA.
Joel KramerMemory and Aging Center, University of California, San Francisco, Sandler Neurosciences Centre, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA.
Alejandro CenturionCommunity Hospital of the Monterrey Peninsula, 100 Clock Tower Pl, Ste 225, Carmel, CA 93921, USA.
Josep DalmauDivision of Neuro-oncology, Department of Neurology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Eric HuangDepartment of Pathology, University of California, San Francisco, 505 Parnassus Avenue, Suite M590, Box 0511, San Francisco, CA 94143, USA.
Jennifer A CotterDepartment of Pathology, University of California, San Francisco, 505 Parnassus Avenue, Suite M590, Box 0511, San Francisco, CA 94143, USA.
Michael D GeschwindMemory and Aging Center, University of California, San Francisco, Sandler Neurosciences Centre, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA. Electronic address: michael.geschwind@ucsf.edu.
University of California, San Francisco · USCommunity Hospital · USHospital of the University of Pennsylvania · US

Funding

UNDERSTANDING AND IMPROVING SMALL MOLECULE INHIBITORS OF PRION REPLICATIONP01AG021601 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRUSINER, STANLEY B · 2003 to 2013
$31.9M
Predicting progression of human prion diseaseR01AG031189 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2008 to 2017
$5.7M
New Clinical Approaches to Creutzfeldt-Jakob DiseaseK23AG021989 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2003 to 2007
$602k
NIA NIH HHS AG21601NIA NIH HHS K23 AG021989NIA NIH HHS P01 AG021601NIA NIH HHS R01 AG031189
6 · The paper itself

Abstract

Autoantibodies associated with autoimmune limbic encephalitis (ALE) have been well-characterized, with intracellular neuronal antibodies being less responsive to immunotherapy than antibodies to cell surface antigens. Adenylate kinase 5 (AK5) is a nucleoside monophosphate kinase vital for neuronal-specific metabolism and is located intracellularly in the cytosol and expressed exclusively in the brain. Antibodies to AK5 had been previously identified but were not known to be associated with human disease prior to the report of two patients with AK5-related ALE (Tuzun et al., 2007). We present the complete clinical picture for one of these patients and the first reported neuropathology for AK5 ALE.

Indexed as

Autoimmune DiseasesLimbic EncephalitisAdenylate KinaseAgedAutoantibodiesHumansMagnetic Resonance ImagingMaleTemporal LobeAdenylate Kinaseadenylate kinase 5AutoantibodiesAdenylate kinase 5AutoimmunityLimbic encephalitisNeuronal antibodiesRapidly progressive dementia

Identifiers

PMID26439959
PMCPMC4879958
OpenAlexW1927105352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.